EP4419087A4 - Pharmaceutical composition containing mirabegron in matrix form - Google Patents

Pharmaceutical composition containing mirabegron in matrix form

Info

Publication number
EP4419087A4
EP4419087A4 EP21968317.4A EP21968317A EP4419087A4 EP 4419087 A4 EP4419087 A4 EP 4419087A4 EP 21968317 A EP21968317 A EP 21968317A EP 4419087 A4 EP4419087 A4 EP 4419087A4
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical composition
composition containing
matrix form
containing mirabegron
mirabegron
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21968317.4A
Other languages
German (de)
French (fr)
Other versions
EP4419087A1 (en
Inventor
Erol Kiresepi
Ersin Yildirim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santa Farma Ilac Sanayi AS
Original Assignee
Santa Farma Ilac Sanayi AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santa Farma Ilac Sanayi AS filed Critical Santa Farma Ilac Sanayi AS
Publication of EP4419087A1 publication Critical patent/EP4419087A1/en
Publication of EP4419087A4 publication Critical patent/EP4419087A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
EP21968317.4A 2021-12-15 2021-12-15 Pharmaceutical composition containing mirabegron in matrix form Pending EP4419087A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/TR2021/051417 WO2023113706A1 (en) 2021-12-15 2021-12-15 Pharmaceutical composition comprising mirabegron in matrix form

Publications (2)

Publication Number Publication Date
EP4419087A1 EP4419087A1 (en) 2024-08-28
EP4419087A4 true EP4419087A4 (en) 2025-09-24

Family

ID=86773294

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21968317.4A Pending EP4419087A4 (en) 2021-12-15 2021-12-15 Pharmaceutical composition containing mirabegron in matrix form

Country Status (2)

Country Link
EP (1) EP4419087A4 (en)
WO (1) WO2023113706A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102062791B1 (en) * 2019-02-26 2020-01-06 신일제약 주식회사 Pharmaceutical formulation for controlled release containing mirabegron or pharmaceutically acceptable salts thereof as an active ingredient

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016188181A (en) * 2015-03-30 2016-11-04 アステラス製薬株式会社 Mirabegron containing release control tablet
KR20180106924A (en) * 2017-03-17 2018-10-01 주식회사 네비팜 Controlled-release pharmaceutical composition
KR20170088783A (en) * 2017-07-07 2017-08-02 지엘팜텍주식회사 Wetgranulation composition containing mirabegron
KR101937713B1 (en) * 2017-07-14 2019-01-14 주식회사 대웅제약 Pharmaceutical formulation and preparation method for the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102062791B1 (en) * 2019-02-26 2020-01-06 신일제약 주식회사 Pharmaceutical formulation for controlled release containing mirabegron or pharmaceutically acceptable salts thereof as an active ingredient

Also Published As

Publication number Publication date
EP4419087A1 (en) 2024-08-28
WO2023113706A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
EP4563151A4 (en) Pharmaceutical composition with KRAS-G12D inhibitor
EP4183391A4 (en) PHARMACEUTICAL COMPOSITION AND USE THEREOF
EP4072520C0 (en) PHARMACEUTICAL COMPOSITIONS WITH CABOTEGRAVIR
PT2269631E (en) PHARMACEUTICAL COMPOSITIONS COMPOSING BOTULINAL NEUROTOXIN FOR USE IN MEDICINE AND COSMETICS
EP4271386A4 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING MELOXICAM
DK2120878T3 (en) Dosage form containing two active pharmaceutical ingredients in different physical forms
EP4221690A4 (en) PHARMACEUTICAL COMPOSITIONS
PA8594801A1 (en) PALANOSETRON LIQUID PHARMACEUTICAL FORMULATIONS
EP4135699A4 (en) PHARMACEUTICAL COMPOSITIONS
EP4037659C0 (en) PHARMACEUTICAL COMPOSITION WITH ENZALUTAMIDE
EP4375300A4 (en) PHARMACEUTICAL COMPOSITION AND USE
EP4247335C0 (en) Pharmaceutical composition with cannabidiol and hyaluronic acid
EP4398909A4 (en) PHARMACEUTICAL COMPOSITION AND USE THEREOF
EP4361174A4 (en) ACYLATED INSULIN-CONTAINING PHARMACEUTICAL COMPOSITION
EP4410292A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING TRIAZINE DERIVATIVE
EP4110301A4 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
EP3981389A4 (en) TOPICALLY ADMINISTRATED PHARMACEUTICAL COMPOSITION IN DISSOLVED FORM WITH EFINACONAZOLE
ZA202213412B (en) Pharmaceutical compositions containing enterokine-releasing substances in multiple dosage forms in combination with gelling agents
EP4436580A4 (en) PHARMACEUTICAL COMPOSITION AND USE THEREOF
EP4419087A4 (en) Pharmaceutical composition containing mirabegron in matrix form
EP4452227C0 (en) PHARMACEUTICAL COMPOSITION WITH SALBUTAMOL
EP4115903A4 (en) PHARMACEUTICAL FORMULATION WITH BEVACIZUMAB
EP4225278A4 (en) PHARMACEUTICAL COMPOSITION OF SIGLEC-BINDING AGENTS
EP4349366A4 (en) PHARMACEUTICAL COMPOSITION
EP4268830A4 (en) PHARMACEUTICAL COMPOSITION

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240524

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20250822

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/20 20060101AFI20250818BHEP

Ipc: A61P 13/10 20060101ALI20250818BHEP

Ipc: A61K 31/426 20060101ALI20250818BHEP